SCHEMBL714461

SCHEMBL714461

Cc1cc(Nc2ccc(S(=O)(=O)Nc3nccs3)cc2)n(Cc2ccc(Cl)cc2)n1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
SCN9A Q15858 5/20 0.54
SCN3A Q9NY46 3/20 0.54
SCN5A Q14524 2/20 0.54
PPIA P62937 3/20 0.53
ALOX12 P18054 1/20 0.50
CCNT1 O60563 1/20 0.49
CDK9 P50750 1/20 0.49
AVPR2 P30518 1/20 0.48
GPR27 Q9NS67 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
SCN1A P35498 1/20 0.46
SCN1B Q07699 1/20 0.46
SCN8A Q9UQD0 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713724 0.92 NAMPT (0.52) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL710057 0.85 SMN1; SMN2 (0.60) LMNASMN1; SMN2SCN9ASCN3APPIA
SCHEMBL712534 0.81 SCN9A (0.54) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL712892 0.81 SCN9A (0.63) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL713144 0.80 SCN9A (0.53) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL713897 0.80 MEN1 (0.54) LMNASMN1; SMN2SCN9ASCN5APPIA
SCHEMBL711684 0.80 LMNA (0.57) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL712431 0.79 SCN9A (0.66) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL3742455 0.78 NAMPT (0.54) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL712299 0.77 SCN9A (0.68) SMN1; SMN2SCN9ASCN3ASCN5AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A LMNA 2921/4885SMN1; SMN2 287/4885SCN9A 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.